What is the recommended use and dosage of Finasteride (finasteride) for benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness)?

Finasteride: Recommended Use and Dosing

Benign Prostatic Hyperplasia (BPH)

For BPH, finasteride 5 mg once daily is the recommended dose, most effective in men with demonstrable prostatic enlargement (prostate volume >30cc), providing sustained symptom improvement over 6-10 years and reducing disease progression, acute urinary retention, and need for surgery. 1, 2, 3

Patient Selection Criteria

• Finasteride is appropriate only for patients with LUTS who have evidence of prostatic enlargement >30cc on imaging 2
• Finasteride is ineffective and should not be used in men with LUTS who lack prostatic enlargement 1, 2
• Greatest benefit occurs in men with larger prostates (≥40cc) and/or higher PSA values (≥1.5 ng/mL) 1, 4

Mechanism and Clinical Effects

• Finasteride inhibits 5-alpha-reductase type II, reducing prostatic DHT by approximately 70%, leading to 15-25% prostate size reduction within 6 months 1, 2
• Patients experience an average 3-point improvement in symptom scores, maintained for 6-10 years 1, 2
• Reduces risk of acute urinary retention by 79% and need for BPH-related surgery by 67% compared to placebo 1, 3

Dosing and Administration

• Standard dose: 5 mg once daily 3
• May be taken with or without meals 3
• Symptom improvement takes 3-6 months to become apparent, with maximum benefit at 6-12 months 1
• Treatment should be continued indefinitely for sustained disease modification 4

Combination Therapy

• Combination with alpha-blocker (tamsulosin 0.4 mg or doxazosin 4-8 mg) plus finasteride 5 mg daily is superior to monotherapy for men with moderate-to-severe symptoms and enlarged prostates 1, 4, 3
• Combination therapy reduces overall clinical progression by 67%, acute urinary retention by 79%, and need for surgery by 67% compared to alpha-blocker alone 1, 4
• Alpha-blocker provides immediate symptom relief while finasteride provides long-term disease modification 1

Critical Monitoring Requirements

• PSA levels decrease by approximately 50% after 12 months of therapy 1, 2
• For prostate cancer screening, double the measured PSA value after 1 year of finasteride therapy to accurately interpret results 1, 2
• Failure to adjust PSA interpretation is a common and dangerous pitfall 2

Adverse Effects

• Decreased libido: 6.4% in first year, decreasing to 2.6% in years 2-4 1, 2, 3
• Ejaculatory dysfunction: 3.7% in first year, decreasing to 1.5% in years 2-4 1, 2, 3
• Erectile dysfunction: 8.1% in first year, decreasing to 5.1% in subsequent years 3
• Gynecomastia: 0.5% in first year, 1.8% in years 2-4 3
• Sexual side effects typically become less common after the first year but may persist in some patients 2, 3

Important Caveats

• Do not use finasteride in patients without prostatic enlargement—it is ineffective 1, 2
• Counsel patients that symptom improvement requires 3-6 months; inadequate treatment duration is a common pitfall 2
• The PCPT trial showed a higher incidence of Gleason score 8-10 prostate cancer (1.8% vs 1.1% placebo), though whether this represents a real increase or detection bias remains debated 5, 3

---

Androgenetic Alopecia (Male Pattern Baldness)

For androgenetic alopecia, finasteride 1 mg once daily is the FDA-approved dose, demonstrating significant improvement in hair growth and density with a favorable safety profile. 6, 7

Dosing and Administration

• Standard dose: 1 mg once daily 6, 7
• Optimal dose established through clinical trials 7
• Long-term use (up to 5 years) has been studied in placebo-controlled trials 7

Mechanism of Action

• Inhibits type 2 5-alpha-reductase, preventing conversion of testosterone to DHT 6
• DHT reduction results in significant improvement in subjective and objective assessments of hair growth and density 6

PSA Considerations for Hair Loss Patients

• Men aged 40-49 years on 1 mg finasteride experience a median 40% decrease in serum PSA by 48 weeks 8
• Men aged 50-60 years on 1 mg finasteride experience a median 50% decrease in serum PSA by 48 weeks 8
• The existing recommendation to double PSA values for prostate cancer screening in men taking 5 mg finasteride should also apply to men taking 1 mg finasteride for hair loss 8

Adverse Effects

• Reduced libido 6
• Decreased ejaculate volume 6
• Gynecomastia 6
• Generally well-tolerated with favorable adverse event profile 6, 7

Common Pitfall

• Failing to adjust PSA interpretation in men aged 40-60 years taking 1 mg finasteride for hair loss—these patients require the same PSA doubling adjustment as those on 5 mg for BPH 8